Documenting Pharmacogenomic Testing with CPT Codes.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Pharmacogenomics in practice: a review and implementation guide.Frontiers in pharmacology · 2023
   Review
2. Opportunities for personalizing colorectal cancer care: an analysis of SEER-medicare data.The pharmacogenomics journal · 2022
   Article
3. Expanding evidence leads to new pharmacogenomics payer coverage.Genetics in medicine : official journal of the American College of Medical Genetics · 2021
   Article
4. Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects.Clinical pharmacology and therapeutics · 2018
   Review
5. Preemptive Panel-Based Pharmacogenetic Testing: The Time is Now.Pharmaceutical research · 2017
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as